retatrutide phase 2 trial obesity nejm 2023 This data from 3 clinical trials for was announced yesterday at @amdiabetesassn #ADA2026 ✓ We are fortunate to be living in a time where there multiple medications which safely reduce Weight Regain after Stopping Obesity

GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO Study

@LillyPad #medtwitter #endotwitter pubmed.ncbi.nlm.nih.gov/35985340/ #retatrutide is a novel triple agonist peptide at the glucagon receptor, GIP receptor, and GLP-1 receptor

If new symptoms arise after a dose increase, they frequently disappear again as your body adapts

It helps: Stimulate insulin release Reduce glucagon production Slow gastric emptying Control appetite Improve blood sugar balance When GLP 1 hormone levels are balanced, your body manages glucose better and hunger cravings reduce